Enfortumab vedotin-ejfv for the treatment of advanced urothelial carcinoma.
Charlene M MantiaGuru SonpavdePublished in: Expert review of anticancer therapy (2022)
Enfortumab vedotin-ejfv has shown promising efficacy and safety in pretreated patients with advanced urothelial carcinoma. It is currently being evaluated in clinical trials in earlier lines of treatment and in combination therapy.